CB-839 (telaglenastat)

telaglenastat · Calithera Biosciences

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CB-839 (telaglenastat), covering 2018-07-18 to 2018-07-18. Get the full timeline:

Most recent: Clinical Trial Update: Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors [Phase 1]